Immune signals may help explain and predict patient responses to therapies through blood and tissue biomarkers tied to treatment outcomes

Immune signals may help explain why patients respond differently to treatment and may allow clinicians to predict outcomes using biomarkers found in blood and tissue. The focus is on measurable immune activity linked to therapeutic response rather than on psychedelic treatment. Researchers at MD Anderson frame these signals as tools for understanding treatment effectiveness, identifying likely responders, and improving how therapies are matched to individual patients. Blood-based and tissue-based indicators could support earlier decisions about treatment strategy and help refine precision medicine approaches in clinical care. The broader significance lies in translating immune profiling into more personalized oncology practice. Better prediction of response could reduce ineffective treatment exposure, guide monitoring, and improve the design of future therapeutic combinations and trials.